Archives

Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting

B BOSTON, April 28, 2026 /PRNewswire/ — Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two… Login to continue reading Login…

Read MoreAscidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting

Hep B Free and Coalition for Global Hepatitis Elimination (CGHE) Announce Strategic Partnership to Accelerate and Scale Hepatitis B Elimination

B SAN FRANCISCO, April 28, 2026 /PRNewswire/ — Hep B Free and the Coalition for Global Hepatitis Elimination (CGHE), a program of The Task Force… Login to continue reading Login…

Read MoreHep B Free and Coalition for Global Hepatitis Elimination (CGHE) Announce Strategic Partnership to Accelerate and Scale Hepatitis B Elimination

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer

B – Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and… Login to continue reading Login…

Read MoreImmunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer